EIF2A and cancer: The abundance of phosphorylated EIF2α was also significantly elevated in cancer (p = 0.0125) (Figure 3, Supplementary Figure S6), consistent with the hypothesis that cancers benefit from the cytoprotective aspect of increased basal EIF2α phosphorylation.